[High dose intravenous immunoglobulins in treating systemic lupus erythematosus-associated thrombocytopenia].
OBJECTIVE
To study the effect of high dose intravenous immunoglobulins(IvIg) in systemic lupus erythematosus (SLE)-associated thrombocytopenia.


METHODS
A case-control study was undertaken to assess the effectiveness of different therapeutic regimens (oral prednisone, IvIg, bolus methylprednisolone(MP), and IvIg plus bolus MP) in improving SLE-associated thrombocytopenia.


RESULTS
For SLE-associated thrombocytopenia, IvIg, bolus MP, and IvIg plus bolus IvIg significantly shorten the time to reach a peak platelet count, which was (6.2 +/- 4.4) days, (7.3 +/- 4.9) days, and (3.8 +/- 2.4) days respectively in comparison with oral prednisone, which was (31.0 +/- 17.8) days (P< 0.01); if high dose IvIg and MP in combination, the time was also shorter than bolus MP alone (P < 0.05). The elevation of platelet count in groups receiving IvIg, bolus MP, and IvIg plus bolus MP were significantly higher than as in group receiving oral prednisone therapy(P < 0.05).


CONCLUSIONS
High dose IvIg is a useful therapy in improving SLE-associated thrombocytopenia.
Zhang
X
X
Department of Rheumatology, PUMC Hospital, CAMS, PUMC, Beijing 100730, China. zhangxuan@csc.pumch.ac.cn
Dong
Y
Y
Tang
F
F
Zhang
F
F
Li
H
H
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007116:Immunization, Passive; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008297:Male; D013921:Thrombocytopenia / Q000209:etiology / Q000628:therapy*; D016896:Treatment Outcome
D016756:Immunoglobulins, Intravenous